Podcasts about baylor college

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join leading experts Fariha Abbasi-Feinberg, MD, FAASM, Medical Director of Sleep Medicine at Millennium Physician Group and President Elect for the American Academy of Sleep Medicine; Inderpreet K. Madahar, MD, MBBS, Assistant Professor of Endocrinology, Diabetes, and Metabolism at Corewell Health; and Sarah Nadeem, MD, FACE, Assistant Professor, Section of Endocrinology, Diabetes, and Metabolism at Baylor College of Medicine, Houston, TX, as they discuss the complex relationship between obstructive and central sleep apnea and metabolic disorders such as obesity and type 2 diabetes.Key topics include:Who should be screened for sleep apnea and the recommended screening toolsFirst-line and adjunctive therapies for managementThe evolving role of multidisciplinary careHow clinical practice is shifting with the recent FDA label expansion of tirzepatide (Zepbound®)When tirzepatide may be considered alongside or in place of CPAP, APAP, and BiPAP therapiesTune in for practical insights to better identify, manage, and support patients at risk. This episode is made possible through a sponsorship from Lilly.

Thomas McGinn, MD, MPH, SEVP, Chief Physician Executive Officer and guests Dr. Ankita Sagar, System VP for Clinical Standards and Variation Reduction, and Dr. Hana El Sahly, Professor Molecular Virology and Microbiology, Baylor College of Medicine discuss the upcoming fall virus season, including a look at vaccine guidance and recommendations for flu, COVID-19, RSV, and pneumococcal disease.

Dr. Hafeez Diwan: The Power of 'Meh', Writing Passions, and Handling Obnoxious PeopleIn this episode of The Girl Doc Survival Guide, Dr. Hafeez Diwan, Professor of Pathology, Immunology, and Dermatology at Baylor College of Medicine, shares insights on his diverse writing endeavors, from self-help books to a young adult sci-fi fantasy novel co-authored with his daughter. Highlighting ideas from his books 'The Power of Meh' and 'How to Love Obnoxious People,' Dr. Diwan discusses strategies for managing emotions, overcoming willpower challenges, and promoting mindfulness. He also reflects on his medical journey and the interplay between his writing and his medical practice.00:00 Introduction to Dr. Hafeez Diwan00:58 Anecdote from Residency02:50 The Writing Journey Begins05:18 The Power of Meh07:26 Loving Obnoxious People11:12 Mastering Willpower14:40 Final Thoughts and Advice

Listen to today's podcast... When you think of stress and food, you are often told to stay away from treats, like ice cream cones. Ice cream: My favourite food. Creamy. Cold. Sweet. Hard or Soft…doesn't matter. I love ice cream. It can be high in fat and it contains a lot of sugar. And it's not the kind of snack food that I should have everyday…though wouldn't that be absolutely wonderful? An ice cream cone has some definite pros. Ice cream may help in maintaining weight. How interesting is that?  Ice cream for weight control.  Research from the American Society of Experimental Biology found that a diet that included dairy prevented about 50 percent of weight regain and 80 percent of fat regain after the animals had lost weight and were allowed to eat at will.  Now this research was done with animals, but if it works there it may work on humans….I would at least like to be a part of the experimental group…test group…not the control group. Ice cream may help me to keep my girlish figure. The North American Association for the Study of Obesity found in a study of 800 men and women that those who ate the most calcium were also the leanest. Research from Baylor College of Medicine and Texas Woman's University in Houston reported an association between the consumption of low-fat milk and dairy products and a lower waist-to-hip ratio. Ice cream may keep me from shrinking. Calcium is essential in preventing osteoporosis.  One reasonable (insert small) serving of ice cream can give you 10% of your daily calcium intake.  Did you know that: Ice cream is not a new treat…people have been creating frozen delicacies since 400 BC Britain's Margaret Thatcher was part of a research team that helped to develop soft ice cream The average American eats 18.3 litres of ice cream each year while Canadians eat 8.7 litres.  Japan has the lowest consumption with .01 litres per year. Take One Action Today To Build Your #Resiliency!      Here are my tips For Building Resilience By Celebrating National Ice Cream Cone Day: Ice cream can be a healthy treat.  But it is a treat.  I have nothing else…just go out and celebrate. Now which kind to choose…DQ, Kawartha Dairy, soft, hard, dipped, sauced, fruit, chocolate….. #mentalhealth #hr

Dr. Tanya Thomas and Dr. Aparna Jotwani join the podcast to discuss the new Oncology Nursing Society and American Society of Clinical Oncology evidence-based guideline on the management of antineoplastic extravasation. They discuss recommendations from the expert panel on: management of extravasation of vesicant or irritant with vesicant properties antineoplastic agents, management of extravasation of paclitaxel or docetaxel, use & duration of thermal compress, and escalation of care. They share the importance of this comprehensive interdisciplinary guideline, highlight the algorithm as a useful tool for clinicians, and outline the outstanding questions related to the management of extravasation. Read the full guideline, “ONS/ASCO Guideline on the Management of Antineoplastic Extravasation” at www.asco.org/supportive-care-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/supportive-care-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the JCO Oncology Practice, https://ascopubs.org/doi/10.1200/OP-25-00579  Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Tanya Thomas, clinical chair of the guideline and clinical nurse specialist from University of Virginia Health, and Dr. Aparna Jotwani, medical oncologist from Baylor College of Medicine, authors on "Management of Antineoplastic Extravasation: Oncology Nursing Society – American Society of Clinical Oncology Guideline." Thank you for being here today, Dr. Thomas and Dr. Jotwani. Dr. Aparna Jotwani: Thank you. Dr. Tanya Thomas: Thank you for having us. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Thomas and Dr. Jotwani, who have joined us here today, are available online with the publication of the guideline in JCO Oncology Practice, which is linked in the show notes. So then to dive into the content here, Dr. Thomas, could you start us off by providing an overview of both the scope and the objectives of this guideline? Dr. Tanya Thomas: Yes, so the objective of this guideline is to provide the evidence-based recommendations to help support our interdisciplinary teams, including the oncologist, the advanced practice providers, pharmacists, and nurses who are involved in the care and management of patients who are experiencing an extravasation of an antineoplastic agent. While rare, the antineoplastic and certain chemotherapy extravasations are oncologic emergencies. The recommendations are to minimize negative consequences and provide a standardized approach to the care when such an event occurs. Dr. Aparna Jotwani: I would add that our scope is limited to intravenous antineoplastic vesicants, irritants, and irritants with vesicant potential. The scope of the guideline applies to the care team for adult oncology patients receiving treatments through venous access. Outside the scope is management of extravasation during other routes of treatment administration, such as intraperitoneal, intravesical, and hepatic arterial infusion. Our recommendations regarding vascular access for therapy or interventions to prevent extravasations are also outside of the scope for this guideline. Brittany Harvey: Understood. I appreciate that background and understanding what's in scope and what's out of scope for this guideline. So then I'd like to pivot and talk about the key recommendations of this guideline across the clinical questions. So first, Dr. Jotwani, what does the panel recommend for patients with extravasation of vesicant or irritant with vesicant properties antineoplastic agents? Dr. Aparna Jotwani: The panel strongly recommends for all classes where an antidote exists to proceed with using the antidote. Recommendations for paclitaxel and docetaxel are specifically addressed in a recommendation. This is further detailed in Tables 1 and 4 within the guideline. Evidence on the use of antidotes for extravasation is limited to nonrandomized, uncontrolled, observational studies and case series. Placebo-controlled trials on this topic would be unethical. There is also a lack of comparative data for different antidote strategies. However, potential benefits of using the antidotes include tissue preservation and avoiding tissue necrosis. In developing the guidelines, we had an in-person roundtable discussion and weighed risks and benefits to ensure patient safety above all else. Brittany Harvey: I appreciate that description of the recommendation here. So then you just mentioned that there's a specific recommendation for paclitaxel and docetaxel. So what is recommended for those patients with extravasation of paclitaxel or docetaxel? Dr. Aparna Jotwani: So here, we conditionally recommended the specific use of hyaluronidase as the antidote. This was based on five studies that all used hyaluronidase as an antidote to lower the risk of tissue necrosis. In the studies included, with a subgroup of patients that experienced taxane-related extravasation, development of necrosis ranged from 0% to 0.83% among the patients who received an antidote. The potential harms associated with this were likely trivial. Brittany Harvey: Thank you for providing that recommendation as well. So then the next section of the guideline, Dr. Thomas, what does the expert panel recommend for use and duration of thermal compress? Dr. Tanya Thomas: So the expert panel actually recommends the use of thermal compresses, and the recommendations are based on the available literature for the various agents and the actual time frames most frequently used for the compress application. The utilization of a thermal compress is recommended for 15 to 20 minutes at a time for 3 to 4 times daily, at least for the first 48 to 72 hours after that extravasation occurs. The actual frequency and duration may vary based on the extent of the extravasation and the agent involved in that extravasation. The intent of the warm compress is to help disperse the agent and reduce the localized accumulation of the agent, whereas the cold compress, it actually helps prevent the dispersion or the spread of the agent while allowing the antidote to help neutralize that agent. Warm compresses are recommended for extravasations involving the vinca alkaloids, etoposide, oxaliplatin, and the taxanes - paclitaxel and docetaxel - only when coadministering the antidote hyaluronidase. The use of a cold compress is actually recommended for extravasations involving the anthracyclines, antimetabolites, alkylating agents, and taxanes when coadministration of the antidote hyaluronidase does not occur. Brittany Harvey: Understood. Those specific and actionable recommendations are really key for clinical practice. So then, following those recommendations, how does the guideline address escalation of care and surgical referral for patients with central line extravasation? Dr. Tanya Thomas: So this topic actually had a lot of discussion. And while there is not enough evidence to make strong recommendations, the expert panel recognized that surgical referrals should be considered in certain scenarios. Dr. Aparna Jotwani: We discussed that certain scenarios would include high-risk populations, such as patients that are receiving DNA-binding vesicants, those with high-volume estimated extravasation, and those with CTCAE grade 2, which would be erythema associated with symptoms such as edema, pain, induration, and phlebitis, or grade 3, which would be symptoms of ulceration or necrosis or concern for severe tissue damage, or grade 4, where you would have a life-threatening consequence extravasation, may have a greater likelihood of benefiting from surgical referral and/or escalation of care as deemed appropriate. Brittany Harvey: Great. And yes, it's really important to provide all of these recommendations that you've both just gone through, even when we're faced with very low evidence. So then, Dr. Thomas, in your view, what is the importance of this guideline, and how will it impact clinical practice? Dr. Tanya Thomas: So when extravasations occur in the clinical setting, members of the interdisciplinary team can be faced with barriers related to where to look for the information, how to find all the relevant information in one concise place, how to provide education to the patient about how to care for the site of extravasation in the home setting, and also when to escalate to specialized teams. This can actually cause some added stress and anxiety, and in certain circumstances, may lead to delays in efficient management. This guideline provides the resource clinicians have been looking for. It includes comprehensive recommendations for antineoplastic extravasations in one guideline while also providing a one-page algorithm with the key information regarding the management of the extravasations. This allows all levels of providers to have evidence-based recommendations regarding initial management of the extravasation, for instance, how to manage the infusion, key site assessment reminders, available antidotes, and the use of thermal compress; the required documentation, recommended follow-up scheduling, in addition to key aspects of the patient education. This type of guidance is not found in any other single document regarding antineoplastic extravasation. Having this document readily available at the point of care potentially can reduce time required for providers to search for management recommendations and also provide consistency in patient education and follow-up management scheduling. It reduces uncertainty within interdisciplinary teams and can help inform policy development for clinicians to approach extravasations with confidence. Brittany Harvey: Absolutely. I agree that this is an incredible resource for clinicians with the recommendations, the algorithm that you mentioned, and the supporting evidence that underpins these recommendations to really provide both efficient and effective care for patients. So beyond the impact for clinical practice, Dr. Jotwani, how will these guideline recommendations affect patients receiving antineoplastic treatment for cancer? Dr. Aparna Jotwani: Exactly. In addition to the clinical care team, we want to help and benefit our patients. So, oncology patients that experience extravasations are at risk for, aside of the side effects of tissue necrosis and infection, they also are at risk for delay of cancer treatment. In making these guidelines, we kept in mind the cost and the efforts for patients, additional visits that they could incur, additional time and supplies for care of the extravasation, as well as cost. Our guideline aims to provide an evidence-based approach to the care of oncology patients receiving antineoplastic intravenous therapy. While there are gaps in the data due to the nature of these events, based on careful literature review, these guidelines serve as a basis for quality, standardized oncology care during extravasation. Personally, I hope our graphics especially can be used across the systems to guide clinical care. Brittany Harvey: Definitely. We hope that these recommendations improve treatment and treatment outcomes for all patients receiving antineoplastic treatment for cancer. So then you've also just mentioned some gaps in the literature. So Dr. Thomas, I'd like to turn to you to wrap us up and ask, what are the outstanding questions for the management of antineoplastic extravasation? Dr. Tanya Thomas: Yes, that's a good question. Two of the main outstanding questions are related to the management of extravasations involving the novel agents and extravasations involving multi-agent regimens. The current literature regarding how to effectively manage the multi-agent regimens, for instance, there is no clear guidance for managing the extravasation for someone who is receiving a regimen that involves simultaneous administration of, let's say, a vinca alkaloid and an anthracycline. One of those agents requires a warm compress while the other requires a cold compress, and there are different antidotes for those two agents. Additionally, there has not been a lot of published information on the impact of extravasation of those novel agents like the antibody-drug conjugates. With the pace of the drug development, a subgroup of the guideline panelists actually are exploring case reports specific to novel agents to help inform some future work. Brittany Harvey: Yes, we'll look forward to learning more about how to address these ongoing issues and potentially impact guideline recommendations in the future as well. So I want to thank you both so much for your work to develop this incredibly important guideline, and thank you for your time today, Dr. Thomas and Dr. Jotwani. Dr. Aparna Jotwani: Thank you for the opportunity. Dr. Tanya Thomas: Yes, thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. I also encourage you to check out the companion episode on this guideline on the ONS podcast, available on Amazon Music, Apple Podcasts, Spotify, and YouTube Music. And finally, you can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

The Other Side of Yes with Matt McAlister Matt is currently a PhD student in Biomedical Sciences at the Baylor College of Medicine. He studies aging and longevity with the goal of (eventually) extending healthy human lifespan.(nbd) He has two undergraduate degrees, one in philosophy and one in biochemistry, which along with some serious improv chops as a performer, teacher and coach, helps explain what makes this conversation fascinating! We talk about life lessons from improv, including the power of being wrong and agreeing with someone who tells you that you're wrong and the secret to staying young forever! (for reals but you'll have to listen)  LinkedIn: https://www.linkedin.com/in/mdmcalister/ Instagram: https://www.instagram.com/matt.d.mcalister/ X: https://x.com/mdMcAlister Facebook: https://www.facebook.com/matt.mcalister  We would like to thank our title sponsor for season 6, CoVet. Meet the world's most powerful veterinary AI copilot. CoVet's easy AI scribe writes your records and automates your admin work so you can focus on the things that matter most. Get 15% off your first year with the promo code below. Website: https://www.co.vet Promo details: 15% off first-year annual membership Promo code: co.vet/boston2025 or https://app.co.vet/authorization?campaign=boston2025&signup=true  Thanks for listening to Comedicine! Send is a text to let us know what you think!Instagram @comedicine_comedyComedicine FacebookYour host, Dr Sarah BostonDr Sarah Boston is a veterinary surgical oncologist (cancer surgeon for dogs and cats), cancer survivor (ironic, right?), bestselling author, actor and stand up comedian. She is a 2023 graduate of the Humber College Comedy Performance and Writing Program. She is the 2023 recipient of the Tim Sims Encouragement Fund Award, which recognizes and supports promising comedic performers in the early stages of their career She is also the recipient of the Award for Academic Excellence from Humber College because she is a nerd in all aspects of her life. Instagram @drsarahboston www.Drsarahboston.com Representation Book Musical Genius Mark Edwards

Please join HRS Digital Education Committee Vice-Chair, Tina Baykaner, MD, MPH, of Stanford University, as she is joined by Heart Rhythm Society President Mina K. Chung, MD, FHRS, of the Cleveland Clinic, and Konstantinos C. Siontis, MD, FHRS of the May Clinic. The three met up in Altanta at HRX 2025 for this stimulating coversation. This study evaluated whether artificial intelligence applied to single-lead ambulatory ECGs could predict imminent sustained ventricular arrhythmias. Using deep learning models, the researchers demonstrated that AI could identify subtle ECG features preceding arrhythmic events, enabling accurate short-term risk prediction. The findings suggest a potential role for AI-enhanced ECG monitoring to improve early detection and prevention of life-threatening ventricular arrhythmias. To view bonus video recorded LIVE at HRX 2025 in Atlanta, view this episode on Heart Rhythm 365 or the HRX Innovation Hub! Article Authors Laurent Fiorina ∙ Tanner Carbonati∙ Kumar Narayanan ∙ Jia Li ∙ Christine Henry ∙ Jagmeet Singh ∙ Eloi Marijon Read the Article: https://www.heartrhythmjournal.com/article/S1547-5271(23)02195-1/fulltext Podcast Contributors and Disclosures Tina Baykaner, MD, MPH | Stanford University Mina K. Chung, MD, FHRS | Cleveland Clinic Konstantinos C. Siontis, MD, FHRS | Mayo Clinic All relevant financial relationships have been mitigated. T. Baykaner:   •Honoraria/Speaking/Consulting: Volta Medical, Medtronic, Pacemate, Johnson and Johnson, Abbot Medical, Boston Scientific Research: NIH M. Chung: •Honoraria/Speaking/Consulting: University of Chicago, Cedars Sinai Medical Center, Asia Pacific Heart Rhythm Society, NIH, Baylor College of Medicine, Kansas City Heart Rhythm Symposium, American College of Cardiology, Geisinger Health Systems, ABIM, Academy for Continued Healthcare Learning, MediasphereMedical, Western AF Symposium, University of Minnesota, Stanford University, Canadian Heart Rhythm Society •Research: NIH, American Heart Association •Royalty Income: Elsevier, Wolters Kluver •Officer: American Heart Association K. Siontis: •Research: Anumana, Varian Medical Systems •Intellectual Property Right: Anumana •Speaking/Teaching/Consulting: EBAMedSA, AskBio

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Nabil Mansour, MD Artificial intelligence, simulation platforms, augmented reality, and other technological innovations are transforming our approach to GI training. In this expert-led discussion, Dr. Peter Buch sits down with Dr. Nabil Mansour to discuss how we can integrate cutting-edge tools into colonoscopy training while preserving core competencies. Dr. Mansour is an Associate Professor and the Director of the McNair General GI Clinic at Baylor College of Medicine in Houston.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Alexis Shafii, professor of surgery and surgical director of heart transplantation at The Texas Heart Institute at Baylor College of Medicine, about the first in-human BiVACOR total artificial heart implantation. Chapters 00:00 Intro 01:54 JANS 1, Validation of SYNTAX 04:58 JANS 2, Long-Distance ECMO Bridge 09:05 JANS 3, Segmentectomies Made Easy 10:49 JANS 4, MI Total Arterial BG 12:56 Career Center 13:46 Video 1, MI ASD Closure 15:43 Video 2, Basics of MV Surgery 17:03 Video 3, Construct Autologous P MV 20:19 Dr. Shafii Interview 33:37 Upcoming Events 34:56 Closing They discuss the preclinical work and the history behind the development of this innovative device. Dr. Shafii also showcases the device and explains its functionality in detail. They also highlight the first patient who received the BiVACOR total artificial heart implantation and provide insights into learning the nuances of this operation.  Additionally, they explore the critical aspects of explanting the device and the importance of understanding how to explant the heart. Furthermore, they discuss the next steps for gaining approval of the BiVACOR total artificial heart, including the feasibility trial, and speculate on where we might be in five years regarding total artificial heart implantation.   Joel also highlights recent JANS articles on the external validation of SYNTAX score II in a real-world cohort undergoing coronary artery bypass grafting, successful extracorporeal membrane oxygenation bridge to lung transplant with a patient transported from Hawaii to Nashville, Tennessee, USA, robotic-assisted left S3 segmentectomy, and minimally invasive total arterial bypass grafting via left minithoracotomy in obese patients.  In addition, Joel explores direct cannulation for minimally invasive ASD closure, an instructional video for residents on the basics of mitral valve surgery, and how to construct an autologous pericardial mitral valve for infants and small children. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) External Validation of SYNTAX Score II in a Real-World Cohort Undergoing Coronary Artery Bypass Grafting  2.) Successful Extracorporeal Membrane Oxygenation Bridge to Lung Transplant With a Patient Transported From Hawaii to Nashville, Tennessee  3.) Segmentectomies Made Easy Series: Robotic-Assisted Left S3 Segmentectomy  4.) Minimally Invasive Total Arterial Bypass Grafting via Left Minithoracotomy in Obese Patients  CTSNet Content Mentioned  1.) Minimally Invasive ASD Closure: Direct Cannulation   2.) Basics of Mitral Valve Surgery: An Instructional Video for Residents   3.) How to Construct an Autologous Pericardial Mitral Valve for Infants and Small Children   Other Items Mentioned  1.) Career Center   2.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

When bad journalism and moneyed interests collide, science suffers. Peter J. Hotez is dean of the National School of Tropical Medicine and professor of pediatrics and molecular virology and microbiology at Baylor College of Medicine – and he played a key role in developing the Covid-19 vaccine. He joins host Krys Boyd to discuss how anti-science factions have hijacked the conversation and his many failed attempts to HHS Secretary Robert F. Kennedy Jr. onboard with vaccines. His book, written with Michael E. Mann, is “Science Under Siege: How to Fight the Five Most Powerful Forces that Threaten Our World.” Learn about your ad choices: dovetail.prx.org/ad-choices

In this episode of SoundPractice, host Mike Sacopulos sits down with Peter Hotez, MD, PhD, professor of pediatrics and molecular virology, Baylor College of Medicine and the co-author of the new book (with Michael Mann) Science Under Siege: How to Fight the Five Most Powerful Forces that Threaten Our World. Hotez pulls back the curtain on the alarming rise of anti-science movements that are costing lives and threatening public health. From vaccine misinformation that led to 200,000 preventable COVID deaths in America to a tragic measles outbreak fueled by unvaccinated populations, he reveals the five powerful forces driving the war on science: - Plutocrats: Wealthy donors funding anti-science think tanks. - Petro-states: Governments opposing climate and health science for profit. - Pros: Credentialed experts pushing contrarian agendas. - Propagandists: Media amplifying misinformation. - Press: Outlets promoting false "both sides" narratives. Hotez also traces the evolution of the anti-vaccine movement, from debunked autism claims to today's wellness influencers profiting off pseudoscience. He challenges medical professionals to embrace the "art" of medicine and step up as defenders of scientific truth. His call to action is clear: silence and invisibility allow bad actors to win. Physicians remain heroes on the frontlines, but they must help turn the tide against misinformation. This must-listen episode is for anyone passionate about science, medicine, and the fight for public health. Tune in to learn how we can push back against disinformation and secure a healthier future for all. Learn more about the American Association for Physician Leadership at www.physicianleaders.org.

Send us a textAging, tissue repair, and the longevity benefits of psilocin.Episode Summary: Dr. Louise Hecker discusses her research on tissue repair and regeneration, explaining how fibroblasts drive wound healing by forming scar tissue but fail to resolve properly with age, leading to fibrotic diseases like pulmonary fibrosis and liver cirrhosis; they discuss aging hallmarks such as oxidative stress and telomere shortening, and highlight Hecker's study showing psilocybin's active metabolite, psilocin, extends cellular lifespan in lab cultures by reducing oxidants and preserving telomeres, while monthly doses in aged mice improved appearance and survival rates.About the guest: Louise Hecker, PhD is an Associate Professor of Medicine at Baylor College of Medicine, specializing in repair and regeneration processes, particularly in aging and fibrotic diseases.Discussion Points:Fibroblasts are dormant cells that activate during injury to pull wounds closed and form scars, then de-differentiate or die; aging impairs this, causing persistent scarring and disease.Aging reduces the body's regenerative capacity; different organs vary in repair efficiency, with skin healing better than heart tissue.Oxidative stress, like "rust" in the body, accumulates with age due to imbalanced reactive oxygen species production and antioxidant defenses, contributing to cellular damage.Telomeres act as protective DNA caps that shorten with cell divisions, serving as a hallmark of biological aging; sirtuins are master regulators influencing aging processes.Hecker's in vitro study showed psilocin dose-dependently extended fibroblast lifespan by 29-50%, lowering oxidative stress below young cell levels and preserving telomeres.In aged mice (equivalent to 60-65 human years), monthly high-dose psilocybin (15 mg/kg) led to healthier appearance, regrown fur, and 80% survival when controls reached 50% mortality after 10 months.Psilocybin's effects may stem from serotonin receptors expressed in many cell types beyond the brain, suggesting broader anti-aging potential; future work explores mechanisms, optimal dosing, and applications for age-related diseases.Fungi like magic mushrooms represent an under-explored "kingdom" for medicine, with psilocybin's durable effects hinting at systemic impacts on aging.Reference Paper:Study: Psilocybin treatment extends cellular lifespan and improves survival of aged miceRelated content:Support the showAffiliates: Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. For all the ways you can support my efforts

On Monday's show: We preview this week's vote on the Harris County budget. The budget process this year has often been contentious as tensions rise over funding cuts.Also this hour: Dr. Peter Hotez of Baylor College of Medicine discusses his book, Science Under Siege, which examines growing opposition to science and the threat it poses.Then, veterinarian Dr. Lori Teller answers listeners' questions about their pets.And Jeff Balke previews a season-defining week ahead for the Astros and the Monday Night Football matchup between the Texans and the Buccaneers. Watch

In this episode of The Retina Channel Podcast, Dr. Christina Weng, Professor of Ophthalmology at Baylor College of Medicine and Chair of DRCR Retina Protocol AO, discusses the pivotal trial evaluating home OCT monitoring in neovascular age-related macular degeneration (AMD). The conversation reviews the study's rationale, methodology, and key findings, with emphasis on how home-based imaging could transform treatment paradigms, refine injection strategies, and inform the future design of retina clinical trials.

Climatologist Michael Mann and vaccine expert Peter Hotez say we're in an “antiscience superstorm.” It's a movement that has upended federal health agencies, defunded research and weaponized social media and AI to advance its agenda. And now, some of the nation's most vocal antiscience figures are in major positions of power. We talk to Hotez and Mann about their daily battles against disinformation, their personal toll and what we can all do to counter the antiscience threat. Their new book is “Science Under Siege.” Guests: Peter J. Hotez, professor and dean of the National School of Tropical Medicine, Baylor College of Medicine; co-director of the Center for Vaccine Development, Texas Children's Hospital Michael E. Mann, professor of earth and environmental science, University of Pennsylvania; director, Penn Center for Science, Sustainability and the Media Learn more about your ad choices. Visit megaphone.fm/adchoices

In this special episode, host Jeremy Schrand sits down with Jill Brinck, Executive Director of CancerFree KIDS, and Dr. Genevieve Kendall, a CancerFree KIDS grant recipient and pediatric cancer researcher at Baylor College of Medicine. Together, they explore the power of early-stage research funding, the challenges and breakthroughs in treating childhood cancers, and the inspiring mission behind CancerFree KIDS. Dr. Kendall shares insights into her lab's work on fusion-driven rhabdomyosarcoma and how innovative models like transgenic zebrafish are helping uncover new therapeutic targets. Whether you're a parent, a scientist, or someone passionate about making a difference, this episode offers a compelling look at how collaboration and curiosity are driving real change in pediatric oncology. Learn more - CancerFree KIDS home page Learn more about Dr Kendall's research - Kendall Lab | Nationwide Children's Hospital Learn more about CTI - CTI - CRO Specializing In Clinical Research And Consulting  02:03 Jill Brink shares her personal and professional journey that led her to become Executive Director of CancerFree KIDS.  04:02 Why funding early-stage, high-risk research is essential for pediatric cancer, highlighting the lack of profitability and federal support in this space. 05:46 Securing funding for early-stage research presents major challenges, including the need for collaboration between scientists and business leaders.  07:06 How CancerFree KIDS selects research projects, outlining the role of their Scientific Advisory Council and the grant scoring process. 09:26 Success stories driven by CancerFree KIDS funding, including early support for clinical trials and advancements in flash proton therapy. 11:22 Dr. Genevieve Kendall explains the nature of fusion-driven rhabdomyosarcoma and why its aggressive behavior and lack of targeted therapies make it difficult to treat. 13:51 How the CancerFree KIDS grant supported a new partnership and provided seed funding to test a promising research idea. 14:50 The significance of identifying HAS3 as a novel target and how it opens new possibilities for treating rhabdomyosarcoma. 16:35 Dr. Kendall describes the role of transgenic zebrafish in her research and how they help uncover therapeutic targets through comparative oncology. 19:33 Both guests share what excites them most about the future of pediatric cancer research, including innovations in CRISPR and immunotherapy. 22:32 How CancerFree KIDS measures the long-term impact of its grants, citing follow-up funding, startup companies, and FDA projects. 24:19 Jill highlights impactful partnerships and community initiatives, such as Jersey Mike's Day of Giving and the 100-Mile Challenge. 26:15 Details about the 100-Mile Challenge, including its structure and supporting events throughout September. 27:51 How CancerFree KIDS engages with families affected by cancer, ranging from support programs to events that honor children and their journeys. 29:51 The future direction of CancerFree KIDS, including expansion, collaboration, and advocacy efforts with the state of Ohio. 

Dr. Carole Keim welcomes pediatric dermatologist Dr. Teresa Wright, MD, to the podcast to talk about baby skin care, birthmarks, eczema, and anything to watch out for with a baby's skin that could potentially be dangerous. Dr. Wright works at Le Bonheur Children's Hospital in Memphis, Tennessee and is also faculty at the University of Tennessee Medical Center. She shares her journey into pediatric dermatology and explores all manner of common skin concerns, conditions, and questions regarding infants and their skin care with Dr. Keim, based on a wealth of experience and knowledge. Dr. Keim and Dr. Wright open by addressing the little pink or red spots in the middle of a newborn's forehead that are sometimes called angel kisses. The medical term is nevus simplex, and Dr. Wright assures listeners that they're nothing to worry about and will fade over time. They discuss types of newborn skin rashes, such as transient neonatal pustular melanosis, which are normal, before addressing conditions that might need a pediatrician's attention. Baby moles are explained in detail, atopic dermatitis or eczema is described, and Dr. Wright offers insight on how to mitigate or improve child skin dryness, along with tips on avoiding exposure to known irritants and allergens. This episode is full of facts and advice on infant skin, offering a practical guide to what is normal and what might need additional attention.Dr. Teresa Wright, MD:Dr. Wright attended medical school at the University of Massachusetts in Worcester, Massachusetts. She went on to complete a residency in pediatrics at the University of Massachusetts Medical Center. Subsequently, she completed a dermatology residency at the University of Kansas Medical Center and a fellowship in pediatric dermatology at Children's Mercy Hospitals and Clinics in Kansas City, Missouri. She joined the dermatology faculty at Baylor College of Medicine and Texas Children's Hospital (TCH) in January of 2009. In January of 2012, she was promoted to Section Chief of Pediatric Dermatology at TCH. She also served as Co-Director of the Vascular Anomalies Program at TCH from October 2011 through March of 2015. In July of 2015, she returned to her hometown of Memphis, TN to join the dermatology faculty at the University of Tennessee and establish a pediatric dermatology division at LeBonheur Children's Hospital. She has special interests and expertise in the diagnosis and management of hemangiomas and other vascular lesions, as well as pigmented lesions and pediatric melanoma. She is board-certified in pediatric dermatology, dermatology, and pediatrics. She is a member of the American Academy of Dermatology, the American Academy of Pediatrics, and the Society for Pediatric Dermatology.Dr. Wright has special interests and expertise in the diagnosis and management of hemangiomas and other vascular lesions, as well as pigmented lesions and pediatric melanoma.__ Resources discussed in this episode:The Holistic Mamas Handbook is available on AmazonThe Baby Manual is also available on Amazon__Contact Dr. Carole Keim, MDlinktree | tiktok | instagramContact Dr. Teresa Wright, MDwebsite | linkedin

Peter Hotez, MD, PhD, founding dean of the National School of Tropical Medicine, codirector of the Texas Children's Center for Vaccine Development, and professor of pediatrics and molecular virology and microbiology at Baylor College of Medicine and Michael E. Mann, presidential distinguished professor and director of the Center for Science, Sustainability and the Media at the University of Pennsylvania and author of several books and co-author and, together, co-authors of Science Under Siege: How to Fight the Five Most Powerful Forces that Threaten Our World (PublicAffairs, 2025), talk about the specific groups promoting anti-science and how they make fighting the global threats of disease and climate change harder. 

Send us a textIn this episode, we welcome Dr. Bianca Edison, a pediatric sports medicine and orthopedic physician, to discuss the critical issues surrounding youth sports. Dr. Edison shares her journey into sports medicine and emphasizes the importance of balancing athletic activities for young athletes. The discussion covers overtraining, the significance of rest and recovery, the impact of burnout, and practical advice for preventing common sports injuries in children. We also dive into the importance of sleep, quality nutrition, and healthy exercise habits. This episode offers valuable insights for parents, coaches, and young athletes aiming for long-term health and enjoyment in sports. Dr. Bianca Edison is a pediatric sports medicine and orthopedic physician at Children's Hospital Los Angeles and Clinical Associate Professor of Orthopedic Surgery at USC's Keck School of Medicine. She received her MD from Baylor College of Medicine, completed pediatrics internship and residency at UCLA (where she served as Chief Resident), and pursued a sports medicine fellowship at CHLA. Bianca's clinical work focuses on overuse injuries, injury prevention, dance medicine, and concussion—helping young athletes stay healthy and love movement for life.Your Child is Normal is the trusted podcast for parents, pediatricians, and child health experts who want smart, nuanced conversations about raising healthy, resilient kids. Hosted by Dr. Jessica Hochman — a board-certified practicing pediatrician — the show combines evidence-based medicine, expert interviews, and real-world parenting advice to help listeners navigate everything from sleep struggles to mental health, nutrition, screen time, and more. Follow Dr Jessica Hochman:Instagram: @AskDrJessica and Tiktok @askdrjessicaYouTube channel: Ask Dr Jessica If you are interested in placing an ad on Your Child Is Normal click here or fill out our interest form.-For a plant-based, USDA Organic certified vitamin supplement, check out : Llama Naturals Vitamin and use discount code: DRJESSICA20-To test your child's microbiome and get recommendations, check out: Tiny Health using code: DRJESSICA The information presented in Ask Dr Jessica is for general educational purposes only. She does not diagno...

As part of the US HUPO sponsored "Alt Proteomics" series highlighting alternative proteomics things, Ben and Ben sit down to talk with Dr. Olga Dudchenko, Baylor College of Medicine.keywords: structural genomics; Hi-C; DNA Zoo

Dr. Toni Engram is a biological dentist, integrative health coach, and owner of Flourish Dental Boutique in Richardson, TX. A fter her own personal health struggles with an autoimmune disease, Dr. Engram shifted her practice philosophy to focus on whole-body health, and the prevention and safer treatment of oral disease. She has degrees from Texas Christian University and Baylor College of Dentistry. Dr. Engram is a member of the IAOMT (International Academy of Oral Medicine and Toxicology) and the IABDM (International Academy for Biological Dentistry and Medicine). She is SMART certified in safe amalgam removal technique, accredited through the IAOMT, and is a TBI Ambassador through The Breathe Institute. She is also a certified Integrative Health Coach through the Institute of Integrative Nutrition. In this episode, Dr. Engram talks about the difference in approaches in traditional dentistry vs. biological dentistry, and how to eat and supplement to optimize your oral health!     RESOURCES: Learn more about Dr. Engram here: http://www.flourish.dental/ Instagram: @drtoniengram Get 15% off Peluva minimalist shoe with coupon code COACHTARA here: http://peluva.com/coachtara   CHAPTERS: 0:00 Intro 3:30 How biological dentistry is different 8:30 Fluoride free toothpaste 12:15 Mercury amalgams 18:50 Dr. Engram's personal healing journey 24:00 Link between periodontal and heart diseases 30:35 How to fight decay 36:10 Weston A. Price's dental research in native communities 44:00 Insurance issues   WORK WITH ME: Are You Looking for Help on Your Wellness Journey? Here's how I can help you: TRY COACH TARA APP FOR FREE: http://taragarrison.com/app LEVEL UP PROGRAM: http://taragarrison.com/level-up INDIVIDUAL ONLINE COACHING: https://www.taragarrison.com/work-with-me CHECK OUT HIGHER RETREATS: https://www.taragarrison.com/retreats   SOCIAL MEDIA:  Instagram @coachtaragarrison TikTok @coachtaragarrison Facebook @coachtaragarrison Pinterest @coachtaragarrison   INSIDE OUT HEALTH PODCAST SPECIAL OFFERS: ☑️ Upgraded Formulas Hair Test Kit Special Offer: https://bit.ly/3YdMn4Z ☑️ Upgraded Formulas - Get 15% OFF Everything with Coupon Code INSIDEOUT15: https://upgradedformulas.com/INSIDEOUT15 ☑️ Rep Provisions: Vote for the future of food with your dollar! And enjoy a 15% discount while you're at it with Coupon Code COACHTARA: https://bit.ly/3dD4ZSv   If you loved this episode, please leave a review! Here's how to do it on Apple Podcasts: Go to Inside Out Health Podcast page: https://podcasts.apple.com/us/podcast/inside-out-health-with-coach-tara-garrison/id1468368093 Scroll down to the ‘Ratings & Reviews' section. Tap ‘Write a Review' (you may be prompted to log in with your Apple ID). Thank you!

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

In this episode, Journal of Prosthetics and Orthotics editor-in-chief Dr. Steve Gard speaks with Jeremy Sherman, MS, CPO, LPO, associate program director and assistant professor in the Orthotics and Prosthetics program at Baylor College of Medicine. They discuss Sherman's study on developing a hand skills testing methodology for O&P, highlighting the challenges and importance of objectively evaluating student proficiency. The conversation explores the creation and refinement of rubrics, the testing methods used at Baylor, and key findings that showed skill improvement through practice and repetition. Sherman also reflects on the broader implications for O&P educators and how similar methodologies could be adopted by other programs. Show notes JPO article: Development of Hand Skills Testing Methodology for O&P Curriculum   O&P Research Insights is produced by Association Briefings.

In this episode of the SRNA "Ask the Expert" podcast moderated by Dr. GG deFiebre, Dr. Kyle Blackburn and Dr. Benjamin Greenberg discussed the need for updated diagnostic criteria for myelitis. Dr. Blackburn explained the term myelitis and the importance of precise terminologies for accurate diagnoses and research [00:05:10]. Dr. Greenberg elaborated on the advancements in testing and understanding of associated disorders like NMOSD and MOGAD since 2002 [00:11:10]. Both experts stated that the shift from "transverse myelitis" to "myelitis" will aid future research, treatments, and patient care [00:17:27]. They reassured patients that these changes would essentially refine their care but not alter it dramatically [00:23:40]. They encouraged patients to stay informed and communicate with their healthcare providers about these updates [00:28:58].Kyle Blackburn, MD is an Assistant Professor in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He specializes in neuroimmunology and has clinical interests in antibody-mediated neurologic disorders, including autoimmune encephalitis, epilepsy, and ataxias; neurologic complications of cancers, including paraneoplastic disorders and checkpoint inhibitor/CAR T-cell toxicity; and demyelinating disorders, including sarcoidosis, neuromyelitis optica, myelin oligodendrocyte glycoprotein (MOG)-associated disease, and multiple sclerosis. Dr. Blackburn earned his medical degree at the University of Kentucky College of Medicine. He performed his residency in adult neurology at UT Southwestern, serving his final year as Chief Resident, and stayed to complete a fellowship in neuroimmunology, during which he earned the James T. Lubin Clinician Scientist Award from the Siegel Rare Neuroimmune Association (SRNA). He joined the UT Southwestern faculty in 2020.Benjamin M. Greenberg, M.D., M.H.S. is a Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He currently serves as the Vice Chair of Translational Research and Strategic Initiatives for the Department of Neurology. He is also the interim Director of the Multiple Sclerosis Center and the Director of the Neurosciences Clinical Research Center. In addition, he serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program at Children's Medical Center.Dr. Greenberg earned his medical degree at Baylor College of Medicine before completing an internal medicine internship at Chicago's Rush Presbyterian-St. Luke's Medical Center. He performed his neurology residency at the Johns Hopkins School of Medicine. He also holds an M.H.S. in molecular microbiology and immunology from the Bloomberg School of Public Health, as well as a bachelor's degree in the history of medicine – both from Johns Hopkins. Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-Director of the nation's first dedicated Transverse Myelitis Center.Dr. Greenberg splits his clinical time between adult and pediatric patients at William P. Clements Jr. and Zale Lipshy University Hospitals, Parkland, and Children's Medical Center. His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients. 00:00 Introduction00:58 Overview of Myelitis and Diagnostic Criteria02:57 Historical Context and Importance of Updated Criteria05:10 Challenges with Current Terminology11:10 Changes in Understanding and Diagnostic Approaches17:27 Implications for Patients and Clinical Practice23:40 Impact on Research and Future Directions28:58 Patient Advocacy31:17 Conclusion

We love to hear from our listeners. Send us a message.This is Episode 3 of "FDA Fridays," a 4-week special series from Cell & Gene: The Podcast. Host Erin Harris talks to Bambi Grilley, Ph.D., Professor of Pediatrics and the Director of Clinical Research and Early Product Development for the Center of Cell and Gene Therapy (CAGT) at Baylor College of Medicine and Chief Regulatory Officer for ISCT, a leading expert at the forefront of pediatric cell and gene therapy. Dr. Grilley shares her wealth of experience and unique perspective on the most pressing barriers to accessing transformative treatments for children, from logistical and financial challenges faced by families, to systemic and regulatory hurdles in getting therapies from the lab to the clinic.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Are typical mouthwash products effective and are they worth recommending to our patients? Are there any products out there that can actually make a significant difference in our fight against perio disease? Our guest, Dr. Steven Milman, will address these questions and more. Dr. Milman received his dental degree from Baylor College of Dentistry in Dallas, Texas. He completed his Periodontal residency at the University of Texas Health Science Center in San Antonio. He was a researcher in periodontal microbiology and was a full time periodontist in his private practice in Round Rock and Austin, Texas for 36 years. Thanks to our episode sponsors: BISCO - https://www.bisco.com/ Solventum - https://www.solventum.com/en-us/home/oral-care/

#ThisMorning #Wellness | #Liver #Cancer Cases are Expected to #Double by 2050 | Hashem El-Serag, Baylor College of Medicine | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #wellness

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Kenneth Liao, professor of surgery and chief of the Division of Cardiothoracic Transplantation and Circulatory Support at Baylor College of Medicine, about performing the world's first adult robotic heart surgery in the United States using a subxiphoid approach. Chapters 00:00 Intro 02:31 JANS 1, Endocarditis Guidelines 13:02 JANS 2, Hybrid vs Catheter 16:16 JANS 3, Full Sternotomy Trial 18:07 JANS 4, Buttressing the BA 19:05 JANS 5, Intraspinal Vasc Perf 20:15 Career Center 20:37 Video 1, Root Replace & Ann Reconstr 21:56 Video 2, Bi-Atrial Cann for BVAD 24:17 Video 3, Pediatric Device Implant 26:23 Dr. Liao Interview 49:07 Upcoming Events 49:39 Closing They discuss the details of the procedure, including its background, ischemic time, technique, and postoperative outcomes. Additionally, they explore the application of the subxiphoid approach for robotic heart transplants and robotic mitral valve repair vs traditional open-chest (sternotomy) repair. Dr. Liao shares insights into the training and practice required for this operation and discusses the advantages of using robotics in heart transplants. He also reflects on what he would do differently in future procedures.   Joel also highlights recent JANS articles on the surgical implications of the 2023 ESC endocarditis guidelines endorsed by EACTS, the two-year results from the randomized CEASE-AF trial on the durable effectiveness and safety of hybrid ablation vs catheter ablation, a randomized trial on superficial parasternal intercostal plane block and full sternotomy, a comparison of the short- and long-term outcomes in patients undergoing sleeve lobectomy with or without buttressing the bronchial anastomosis, and intraspinal vascular perfusion territories of the descending thoracic aorta.  In addition, Joel explores free-style root replacement and annular reconstruction for destructive aortic root endocarditis, bi-atrial cannulation for biventricular assist device in children, and a device implantation in a 26 kg child. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Surgical Implications of the 2023 ESC Endocarditis Guidelines Endorsed by EACTS: Bridging Guidelines and Practice   2.) Durable Effectiveness and Safety of Hybrid Ablation Versus Catheter Ablation: 2-year Results From the Randomized CEASE-AF Trial  3.) Superficial Parasternal Intercostal Plane Block and Full Sternotomy; A Randomized Trial  4.) Comparison of Short- and Long-Term Outcomes in Patients Undergoing Sleeve Lobectomy With or Without Buttressing the Bronchial Anastomosis  5.) Intraspinal Vascular Perfusion Territories of the Descending Thoracic Aorta  CTSNET Content Mentioned  1.) Free-Style Root Replacement and Annular Reconstruction for Destructive Aortic Root Endocarditis  2.) Bi-Atrial Cannulation for Biventricular Assist Device in Children  3.) Device Implantation in a 26 kg Child  Other Items Mentioned  1.) Guest Editor Series Webinar: Insights Into Pediatric Mechanical Circulatory Support  2.) Cardiac Surgical Arrest—An International Conversation Series    3.) Career Center   4.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

PURCHASE THIS PODCOURSE! If you are a therapist or counselor looking for continuing education, check out my NBCC Approved $5 Podcourses and other continuing education offerings.Plus, get your first Podcourse half off. Since 2009, rates of anxiety, depression, and suicidality among young people have risen sharply, and research points to smartphones and social media as major contributors. In this episode, I talk with Dr. Johann D'Souza, a clinical psychologist specializing in OCD and anxiety, about what is driving this crisis and how we can respond. We unpack the four harmful effects of excessive screen time: sleep deprivation, addiction, social isolation, and distraction. We also explore evidence-based solutions that work. From creating phone-free schools to encouraging unstructured play and family screen detoxes, you will hear practical steps parents, therapists, and communities can take to protect youth well-being.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Todd Rosengart, professor and chair of the Michael E. DeBakey Department of Surgery at Baylor College of Medicine, about his team performing the world's first adult robotic heart surgery in the United States. Chapters 00:00 Intro 02:27 JANS 1, On-Table Extubation 14:13 JANS 2, Intraop Broncho Biopsies 18:26 JANS 3, Stroke After Transplant 20:51 JANS 4, Pulm Carcinoid Tumors 22:56 Career Center 24:05 Video 1, Robotic LAAO 25:36 Video 2, Bedside VV ECMO 26:44 Video 3, Inverted Y AE 28:01 Dr. Rosengart Interview, Novel Approaches 40:57 Upcoming Events 42:58 Closing They discuss postoperative outcomes and the 100-day follow-up appointment, the benefits of the robotic technique in transplants, and the surgeons who participated in this procedure. Additionally, Dr. Rosengart shares advice for individuals performing robotic transplants, his experience leading this unit, and its notable accomplishments, including other world-first procedures.   Joel also highlights recent JANS articles on the 10 best practices of on-table extubation after cardiac surgery, if we can rely on intraoperative bronchoscopic biopsies for surgical decision making, increased prevalence of stroke after heart transplant in the new allocation system era, and the surgical management of both stage III and stage IV pulmonary carcinoid tumors confers survival benefit.  In addition, Joel explores robotic left atrial appendage occlusion, bedside veno-venous extracorporeal membrane oxygenation cannulation technique in an awake patient, and a stepwise surgical approach for inverted Y annular enlargement in the bicuspid aortic valve. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) The 10 Commandments of On-Table Extubation After Cardiac Surgery: Why and How to Increase Adoption  2.) Can We Rely on Intraoperative Bronchoscopic Biopsies for Surgical Decision Making? 78 Single Anesthetic Robotic Bronchoscopy to Anatomic Resections  3.) Increased Prevalence of Stroke After Heart Transplant in the New Allocation System Era  4.) Surgical Management of Both Stage III and Stage IV Pulmonary Carcinoid Tumors Confers Survival Benefit  CTSNET Content Mentioned  1.) Robotic Left Atrial Appendage Occlusion   2.) Bedside Veno-Venous Extracorporeal Membrane Oxygenation Cannulation Technique in an Awake Patient  3.) Inverted Y Annular Enlargement in Bicuspid Aortic Valve: A Stepwise Surgical Approach  Other Items Mentioned  1.) Guest Editor Series: Insights Into Pediatric Mechanical Circulatory Support  2.) Cardiac Surgical Arrest—An International Conversation Series    3.) Career Center   4.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Estás escuchando #JUNTOSRadio: ¿Qué es el lupus?, ¿cómo puedo identificar los síntomas?, ¿esta enfermedad afecta a la comunidad latina? El Doctor Brad Nelson nos responde a estas y otras preguntas. Sobre nuestro invitado: El Dr. M. Brad Nelson es Profesor Clínico Adjunto de Pediatría con un nombramiento conjunto en la División de Alergia, Inmunología Clínica y Reumatología de la Facultad de Medicina de la Universidad de Kansas / Sistema de Salud de la Universidad de Kansas. Después de completar su Maestría en Salud Pública y Doctorado en Medicina en la Facultad de Medicina de la Universidad de Kansas, el Dr. Nelson completó su pasantía y residencia en Pediatría en la Facultad de Medicina de la Universidad de Utah / Hospital Pediátrico Primario en Salt Lake City, UT. Durante su residencia, también completó un programa de certificado en Bioética Pediátrica a través de la Facultad de Medicina de la Universidad de Missouri-Kansas City / Hospital Pediátrico Mercy en Kansas City, MO. Posteriormente, el Dr. Nelson realizó una beca en Reumatología Pediátrica en el Baylor College of Medicine / Hospital Pediátrico de Texas en Houston, TX. Además de brindar atención clínica, el Dr. Nelson tiene intereses en la educación de estudiantes de medicina, residentes y becarios, la investigación en las áreas de determinantes sociales y resultados en enfermedades crónicas pediátricas y la integración de la atención de salud mental en la atención de niños con enfermedades crónicas. Recursos en español Lupus en la comunidad latina: https://www.gladel.org/gladelspa/acer... Facebook: @juntosKS Instagram: juntos_ks YouTube: Juntos KS Twitter: @juntosKS Página web: http://juntosks.org Suscríbete en cualquiera de nuestras plataformas de Podcast: Podbean, Spotify, Amazon Music y Apple Podcast - Juntos Radio Centro JUNTOS Para Mejorar La Salud Latina 4125 Rainbow Blvd. M.S. 1076, Kansas City, KS 66160 No tenemos los derechos de autor de la música que aparece en este video. Todos los derechos de la música pertenecen a sus respectivos creadores.

Bienvenidos a la quinta temporada de Pediatras en Línea, un podcast creado para conectar a profesionales de la salud con experiencias, herramientas y modelos innovadores que están transformando el cuidado pediátrico en nuestras comunidades. Hoy tenemos un episodio dirigido a ustedes: pediatras, médicos de atención primaria, residentes y profesionales que trabajan con pacientes pediátricos hispanohablantes.  Nos acompañan dos cirujanos pediatras de Children's Hospital Colorado que lideran una iniciativa única en su tipo: una clínica de cirugía pediátrica completamente en español. Conoceremos cómo funciona este modelo, su impacto en la atención, y cómo puede servir como inspiración para replicarlo en otros sistemas de salud. El Dr. José Luis Díaz-Mirón es originario de Nuevo Laredo, Tamaulipas, México. Estudió medicina en Baylor College of Medicine, en Houston, Texas y completó su residencia en cirugía general en Washington University School of Medicine, en San Luis, Missouri. La especialidad en cirugía pediátrica la realizó en la Universidad de Michigan, Ann Arbor. El Dr. Jonathan Hills-Dunlap estudió en la escuela de medicina de la Universidad de Stanford. Cuenta con una maestría en salud pública de la Escuela de Salud Pública de Harvard. Su residencia la cursó en Brigham and Women's Hospital y en la Escuela de Medicina de Harvard. Realizó un fellowship de Investigación en Servicios de Salud Pediátrica de Harvard en el Boston Children's Hospital y la subespecialidad de Cirugía Pediátrica en el Children's Hospital Colorado en la Universidad de Colorado. Actualmente ambos trabajan en Children's Hospital Colorado donde han desarrollado la primera clínica en el estado de Colorado para pacientes de habla hispana. Clínica de cirugía pediátrica de habla hispana . Click or tap if you trust this link." id="OWA0ed31062-1cc1-9dc2-f276-b96e9f292da1" href="Clínica de cirugía pediátrica de habla hispana ">Clínica de Cirugía Pediátrica | Children's Hospital Colorado (Children's Hospital Colorado ) ¿Tienes algún comentario sobre este episodio o sugerencias de temas para un futuro podcast?  Escríbenos a pediatrasenlinea@childrenscolorado.org.

CardioNerds (Dr. Rick Ferraro and Dr. Dan Ambinder) join Dr. Sahar Samimi and Dr. Lorraine Mascarenhas from Baylor College of Medicine, Houston, Texas, at the Houston Rodeo for some tasty Texas BBQ and a tour of the lively rodeo grounds to discuss an interesting case full of clinical pearls involving a patient with nonbacterial thrombotic endocarditis (NBTE). Expert commentary is provided by Dr. Basant Arya. Episode audio was edited by CardioNerds Intern Dr. Bhavya Shah. (Photo by Xu Jianmei/Xinhua via Getty Images)Xinhua News Agency via Getty Images We discuss a case of a 38-year-old woman with advanced endometrial cancer who presents with acute abdominal pain, found to have splenic and renal infarcts, severe aortic regurgitation, and persistently negative blood cultures, ultimately diagnosed with nonbacterial thrombotic endocarditis (NBTE). We review the definition and pathophysiology of NBTE in the context of malignancy and hypercoagulability, discuss initial evaluation and echocardiographic findings, and highlight important management considerations. Emphasis is placed on the complexities of anticoagulation choice, the role of valvular surveillance, and the need for coordinated, multidisciplinary care.   US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls- Nonbacterial Thrombotic Endocarditis Eliminate the Usual Suspects. NBTE is a diagnosis of exclusion! Always rule out infective endocarditis (IE) first with serial blood cultures and serologic tests.  More than Meets the Echo. Distinguishing NBTE from culture-negative endocarditis can be tricky. Look beyond the echo—focus on clinical context (underlying malignancy, autoimmune issues) and lab findings to clinch the diagnosis.  TEE for the Win... Mostly. While TEE is more sensitive than TTE, NBTE vegetations can be sneaky and may embolize quickly. Don't hesitate to use advanced imaging (i.e., cardiac MRI, CTA) or repeat imaging if you still suspect NBTE.  Choose your champion. In cancer-associated NBTE, guideline recommendations for anticoagulation choice are lacking. Consider DOACs and LMWH as agents of choice, but ultimately use shared decision-making to guide management.  No obvious trigger? Go hunting for hidden malignancies or autoimmune disorders. A thorough workup is essential to uncover the driving force behind NBTE.  Check out this state-of-the-art review for a comprehensive, one-stop summary of NBTE: European Heart Journal, 46(3), 236–245. Please note that the figures and tables referenced in the following notes are adapted from this review.  notes- Nonbacterial Thrombotic Endocarditis Notes were drafted by Dr. Sahar Samimi.  What is nonbacterial thrombotic endocarditis (NBTE)?   NBTE, previously known as marantic endocarditis, is a rare condition in which sterile vegetations form on heart valves.1  It occurs most commonly in association with malignancies and autoimmune conditions (i.e, antiphospholipid antibody syndrome or systemic lupus erythematosus).1 In addition, NBTE has been reported in association with COVID-19 infection, burns, sepsis, and indwelling catheters.2  Precise mechanisms remain unclear, but an interplay of endothelial injury, hypercoagulability, hypoxia, and immune complex deposition contributes to the formation of these sterile vegetations. 1  How do we diagnose NBTE?  Physicians should have a high level of suspicion for NBTE in at-risk patients (e.g., with active malignancy) who present with recent or recurrent embolic events (i.e., stroke, splenic, renal, or mesenteric infarct, and acute coronary syndrome).1 

Dr. Paul Ling is a professor in the Department of Microbiology and Virology at Baylor College of Medicine. He also serves as an advisor to Colossal Biosciences. Following the death in 2010 of a 2-year-old elephant at the Houston zoo due to elephant endotheliotropic herpes virus (EEHV), Dr. Ling formed a cooperative effort with the zoo and others within the community to address this highly lethal disease. Thanks to this partnership and significant funding from the Houston zoo, a mRNA vaccine was successfully introduced last year to a few vulnerable individuals at the Cincinnati zoo.  Other key partners in the development of diagnostics, therapeutics and ultimately, the vaccine include: Dr. Jeroen Pollet of the National School for Tropical Medicine, the International Elephant Foundation (IEF), Colossal Biosciences, and the Houston Methodist Center for RNA Therapeutics. https://www.houstonzoo.org/houston-zoo-leads-the-way-in-eehv-research/ Animal Care Software

Matthew Halpert, PhD—immunologist and CEO of Immunocine—joins The Moss Report to discuss an important discovery: a new way to fully activate dendritic cells, the “coaches” of the immune system. When these cells switch on, they can recognize and attack cancer. We talk about what this could mean for the future of immunotherapy: approaches that are more targeted, potentially less toxic, and designed to help the body find what it has been missing. Dr. Halpert explains the insight behind the method, how it differs from current treatments, what early experience looks like, and the key questions that still need testing. If you follow immunotherapy—or are weighing options—this conversation captures a major step forward in understanding how the immune system can be guided to fight cancer. Full article on The Moss Report with transcript: https://www.themossreport.com/immunocine-cancer-center/ Glossary of Terms  https://docs.google.com/document/d/140Gt8VNgexyu-2vjfOgTdPdOqlaFAsvLTOVWLyGwGgE/edit?usp=sharing Cited Paper: MHC class I and II peptide homology regulates the cellular immune response - https://pubmed.ncbi.nlm.nih.gov/32298026/ PubMed - Original Article in FASEB  https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.201903002R Immunocine Cancer Center - https://immunocine.com/meet-the-immunocine-team/ Baylor College of Medicine - https://www.bcm.edu/ Resources:

In this episode of the Big T Trauma Series, Dr. Patrick Georgoff (@georgoff) and Dr. Jason Brill dive into the evolving world of Trauma Video Review (TVR) with special guests Dr. Michael Vella and Dr. Ryan Dumas. Together, they explore how TVR is transforming trauma care by offering unprecedented insight into both technical and non-technical performance in the trauma bay. The conversation covers everything from implementation logistics and HIPAA concerns to cultural shifts and emerging AI applications. Whether you're curious about getting started or wondering if TVR should be part of trauma verification, this episode delivers essential insights from two national leaders in the space. Don't miss it! Dr. Ryan Dumas is an associate professor of surgery at Baylor College of Medicine in Houston Texas where he serves as the Section Chief of Acute Care Surgery.  Dr. Dumas conducts and publishes research in trauma surgery and artificial intelligence, with a specific emphasis on video technology to capture and review trauma resuscitations. He has helped develop and run several Trauma Video Review programs across the country and utilizes video review as a tool for quality improvement, education, and research. Dr. Dumas is a consultant for Teleflex and Surgical Safety Technologies. Dr. Michael Vella is an associate professor of surgery, division of acute care surgery and trauma, at the university of Rochester medical center in Rochester, NY and the trauma medical director of the Kessler Level I trauma center.  He currently serves as chair of the New York State Committee on Trauma.  He has a clinical and research interest in trauma video review, particularly as it relates to trauma team dynamics and initial resuscitation.  Dr. Dumas is a consultant for Teleflex. This episode of Big T Trauma was sponsored by Teleflex, a global provider of medical devices. Learn more at teleflex.com and at the Teleflex Trauma and Emergency Medicine LinkedIn page. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

In this episode, Journal of Prosthetics and Orthotics editor-in-chief Dr. Steve Gard sits down with Jeremy Sherman, MS, CPO, LPO, the associate program director for the orthotics and prosthetics program, and an assistant professor in the School of Health Professions at Baylor College of Medicine. Together, they explore Sherman's research on ergonomic challenges, overuse injuries, and the widespread prevalence of pain among O&P professionals across the U.S. Drawing from his background in mechanical engineering and patient-centered care, Sherman shares what led him to investigate the physical toll of clinical work. The conversation highlights key findings, including the disproportionate impact on early-career practitioners and the critical need for more adaptable, ergonomic clinical environments to ensure career longevity and provider well-being. Show notes JPO article: Insights into Overuse: Ergonomic Trends and Pain Prevalence Among Orthotics and Prosthetics Practitioners in the United States   O&P Research Insights is produced by Association Briefings.

In this episode of the Dr. Geo Prostate Podcast, Dr. Geo welcomes Dr. Mohit Khera, a globally recognized leader in men's health, Professor of Urology and Director of the Executive Health Program at Baylor College of Medicine. With over 160 peer-reviewed publications and decades of clinical experience in testosterone therapy, male infertility, and prostate health, Dr. Khera shares cutting-edge insights on testosterone replacement therapy (TRT), including the rise of oral testosterone like Kyzatrex, and the evolving understanding of testosterone's relationship to prostate cancer.Whether you're considering TRT, recovering from prostate cancer, or supporting a loved one's health journey, this conversation brings clarity to one of men's most pressing health topics.What You'll Learn:The 4 C's framework to determine the best TRT option:Cost, Compliance, Convenience, ConcentrationWhy oral testosterone (Kyzatrex, Tlando, Jatenzo) is gaining traction—and what makes them differentHow Kyzatrex may help preserve fertility by reducing gonadotropin suppressionWhat the TRAVERSE trial revealed about TRT and cardiovascular safetyWhy low testosterone may be linked to more aggressive prostate cancerWhat the latest science says about BAT (Bipolar Androgen Therapy) for advanced prostate cancerThe truth about testosterone's impact on BPH and urinary symptomsWhy total testosterone isn't enough—labs like SHBG, DHT, estradiol, and free testosterone matterKey Insights:TRT doesn't cause prostate cancer — and may even have protective effects in some men.Testosterone is the best barometer of male health—predicting cardiovascular risk, mood, bone density, and more.BAT (Bipolar Androgen Therapy) is showing promise in treating advanced prostate cancer in specific scenarios.Avoid unnecessary aromatase inhibitors and DHT blockers unless clinically indicated.

Remembering why you first entered the wonderful and challenging world of academic medicine might be just the boost of joy you need to uncover to stave off burnout. Our guest this week on the Faculty Factory Podcast is Geeta Singhal, MD, MEd, FAAP, whom we warmly welcome for her first-ever (and very memorable) appearance on our program. She does a brilliant job painting a picture for us of ways to uncover joy amidst the challenges of patient care, teaching, research, and many other rich, rewarding, and difficult tasks of the academic medicine journey. Dr. Singhal currently serves as Executive Vice Chair of the Department of Pediatrics, Professor of Pediatrics, Director of Academics in the Division of Pediatric Hospital Medicine, Attending Physician, and Co-Director of Pediatric Hospital Medicine at Baylor College of Medicine (BCM). She is also a Faculty Leadership Development Program Partner at BCM and a Professionalism Partner at Texas Children's Hospital.  Learn more: http://facultyfactory.org/Geeta-Singhal 

Want to elevate your infection prevention career? Dive into this inspiring episode with Gail Fraine and Dr. Mayar Al Mohajer as they explore the value, purpose, and impact of the Advanced Leadership Certification in Infection Prevention (AL-CIP). Learn how this credential empowers professionals to lead change, drive outcomes, and shape healthcare policy. Get tips for submission success and hear firsthand experiences from these certified leaders! Hosted by: Kelly Holmes, MS, CIC, FAPIC and Lerenza L. Howard, MHA, CIC, LSSGB About our Guests: Gail Fraine, CIC, LTC-CIP, AL-CIP Gail Fraine is the System Director of Infection Prevention at Ascension Saint Thomas in Nashville, TN, with over 30 years of experience reducing healthcare-associated infections through evidence-based practices and high-reliability principles. A long-standing APIC member, she has held national leadership roles including Board Director and Annual Conference Chair. Gail currently serves as President-Elect of the Certification Board of Infection Control and Epidemiology (CBIC) and contributed to developing both the long-term care and Advanced Leadership certifications. She holds nursing degrees from Arkansas State, Belmont, and Vanderbilt, and is certified in CIC, LTC-CIP, and AL-CIP. Mayar Al Mohajer, FIDSA, FSHEA, FAPIC, FACHE, AL-CIP Dr. Al Mohajer serves as Professor of Medicine in the Section of Infectious Diseases at Baylor College of Medicine in Houston, Texas, where he also directs the Infection Prevention, Antimicrobial Stewardship, Quality Improvement, and Leadership Track. He is the Chief of the Infectious Disease Section at Baylor St. Luke's Medical Center and the Medical Director of Infection Prevention, Occupational Health, Diagnostic Stewardship, and Antibiotic Stewardship for CommonSpirit Health's South Region and Baylor St. Luke's Medical Center. In addition to his clinical and academic roles, Dr. Al Mohajer sits on the CBIC Board and co-chairs the National Infection Prevention Council for CommonSpirit Health. He holds multiple fellowships and certifications recognizing his expertise and leadership, including FIDSA, FSHEA, FAPIC, FACHE, and AL-CIP.

Dr. Madhuri Vasudevan is a board-certified endocrinologist and faculty member at Baylor College of Medicine, known for her integrative approach to healing that unites science, nutrition, and holistic wellness. Through her work--especially with veterans at the VA--she empowers patients to thrive by harnessing their body’s natural ability to heal, using both medical therapies and lifestyle-based […]

In episode 51 of Going anti-Viral, Dr Peter Hotez joins host Dr Michael Saag to provide an update on the measles outbreak in the US and discuss the role that anti-science plays in threatening public health. Dr Hotez is a Professor of Pediatrics and Molecular Virology and Microbiology at Baylor College of Medicine. He is the author of more than 700 scientific papers and four books and is an ardent vaccine advocate and “science explainer” who combats anti-science and antisemitism in America, and globally. Dr Hotez and Dr Saag provide an overview of the current measles outbreak in the United States and the high rate of transmission. They discuss efforts to increase rates of vaccination, especially in a climate of misinformation about the safety and efficacy of the measles vaccine. Dr Saag and Dr Hotez discuss the origins of misinformation during the COVID-19 pandemic, including a discussion of the incentives of health and wellness influencers to spread false information. They also discuss how best to distribute accurate health information about vaccines on social media. They conclude by reviewing the successful history of childhood vaccination programs and the risk of future pandemics in a climate of disinformation about vaccination. 0:00 – Introduction1:56 – Measles and risk of transmission 6:24 – Efforts to increase rates of vaccination and discussion of anti-vaccine sentiment  10:40 – Growth of anti-vaccine sentiment during COVID-19 and health and wellness influencers distributing false health information 17:46 – How to best to distribute accurate health information on social media 22:35 – Conflict of interest among anti-vaccine influencers 27:47 – The success of childhood vaccination and the risk of future pandemics given vaccine disinformation __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode, Dr. Alexis Wood, a leading researcher at Baylor College of Medicine, joins me to unpack insights into childhood nutrition, genetics, and cognitive health. Dr. Wood's work bridges genetics, dietary practices, and brain development, highlighting how early-life nutrition can shape lifelong outcomes. We explore cutting-edge research, practical strategies for parents, and the surprising factors influencing children's cognitive and metabolic health.We cover:Why childhood nutrition and genetics have been historically overlooked—and what it means for your family.ADHD and diet: Separating fact from fiction.Debunking popular diet myths: What the research actually says about red meat and processed foods.Cognitive self-regulation: The hidden link between diet, obesity, and ADHD. Precision nutrition & metabolomics: The future is more than one-size-fits-all advice.Whether you're a parent, educator, or health professional, this conversation offers guidance on navigating the complex relationship between nutrition, genetics, and childhood development.Who is Dr. Alexis Wood?Dr. Alexis Wood, Ph.D., F.A.H.A., is an Associate Professor of Pediatrics–Nutrition at Baylor College of Medicine's USDA/ARS Children's Nutrition Research Center. Her research integrates genetics, child development, and nutrition, focusing on how genetic factors influence responses to diet and behavior.This episode is brought to you by: PaleoValley - Get 15% off at https://paleovalley.com/drlyonARMRA – Use code DRLYON to get 15% off your first order at https://tryarmra.com/DRLYONOur Place - Use code DRLYON for 10% off sitewide – https://fromourplace.com/DRLYON Timeline - Get 20% off your order of Mitopure - https://timeline.com/LYONFind Dr. Alexis Wood at: Linked In - https://www.linkedin.com/in/lekkiwood/Baylor College of Medicine - https://www.bcm.edu/people-search/alexis-wood-33281USDA/ARS Children's Nutrition Research Center - https://www.bcm.edu/research/research-centers/usda-ars-childrens-nutrition-research-centerAlexis Wood Lab - https://www.bcm.edu/research/faculty-labs/alexis-lekki-wood-labFind Me At: Instagram:@drgabriellelyon TikTok: @drgabriellelyonFacebook: facebook.com/doctorgabriellelyonYouTube: youtube.com/@DrGabrielleLyonX (Twitter): x.com/drgabriellelyonApply to become a patient –

I'm joined today by two special guests to discuss an unusual and ethically complex type of organ donation – imminent death donation, or IDD. As you'll hear Thao Galvan explain in the episode, organ donation currently has three standard types: living donation, donation after brain death (a type of deceased donation in which the patient is declared brain dead, and thus legally dead), and donation after circulatory death, or DCD. In DCD, a patient who is not brain dead is removed from life support, but the heart keeps beating. If it takes the patient more than roughly 90 minutes to die, the organs may not be usable. IDD, or imminent death donation, attempts to prevent that, by retrieving non-vital organs (usually a kidney) for donation prior to the removal of life support. Thao Galvan is a transplant surgeon and professor of surgery at Baylor College of Medicine. Kathy Osterrieder is a retired financial analyst, who came to this issue after attempting, unsuccessfully, to donate the organs of her late husband, Robert Osterrieder, after making the difficult decision to remove him from life support. It is another first for the Taboo Trades podcast – the first time in over five years of recording that I've been unable to hold back the tears, as Kathy talks about what the experience was like for her family. LinksHost: Kimberly D. Krawiec, Charles O. Gregory Professor of Law, University of VirginiaGuests: Nhu Thao Nguyen Galvan, M.D., M.P.H., FACS, Associate Professor of Surgery, Baylor College of MedicineKathleen Osterrieder, Donor Family Member in Spirit, Retired Financial AnalystReading: The Difficult Ethics of Organ Donations From Living Donors, Wall St. J. (2016)Let's change the rules for organ donations — and save lives, Wash. Post (2019)OPTN, Ethical considerations of imminent death donation white paper (2016)Survey of public attitudes towards imminent death donation in the United States, Am. J. Transplant. (2020)

What if instead of treating illness we also confronted the reasons Americans get sick in the first place? That's the origin of this podcast and also the 4 billion dollar question Dr. Bechara Choucair is tackling at Kaiser Permanente. Bechara, who is KP's Chief Community Health Officer, joins Claudia to talk about the organization's focus on climate change and health, workforce pipelines and addressing broader social needs.We discuss:The surprising fact that two-thirds of KP's members (who are mostly covered by employer insurance) have at least one unmet social needThe common sense moves the Common Health Coalition is taking to build bridges between healthcare and public healthWhat KP is doing to tackle a big problem limiting the mental health workforce: only 57% of masters trained therapist get licensedWhat it took for KP to achieve carbon neutralityBechara reminds us that bridge-building is a crucial part of this community health work:“We need more and more bridges between public health and healthcare... [They have] operated as two separate disciplines operating in their own silos... [When] there is a public health emergency we build more bridges, we strengthen those bridges that already exist. And then when that public health emergency subsides, we all retreat into our own disciplines and we continue that siloed journey.”Relevant LinksRead about the NAM initiative on climate change and healthExplore why the US needs more community health workers from this articleLearn more about the Common Health CoalitionDive into details on KP's sustainability journeyAbout Our GuestDr. Bechara Choucair, MD, is executive vice president and chief community health officer for Kaiser Foundation Health Plan, Inc. and Hospitals — known as Kaiser Permanente, one of America's leading integrated health care providers and not-for-profit health plans. Dr. Choucair oversees the organization's national community health efforts and philanthropic giving activities aimed at improving the health of its 12.2 million members and the 68 million people within the communities it serves.Previously, Dr. Choucair served as senior vice president, Safety Net and Community Health, at Trinity Health, and was the commissioner of the Chicago Department of Public Health.Dr. Choucair, a family physician by training, completed his Family Practice Residency at Baylor College of Medicine in Houston, Texas. He holds an MD from the American University of Beirut and a master's degree in health care management from the University of Texas at Dallas.SourceConnect With UsFor more information on The Other 80 please visit our website - www.theother80.com. To connect with our team, please email claudia@theother80.com and follow us on twitter

Intern year: where the learning curve is steep and you're not sure if the patient is crashing or you are. In this episode of Behind the Knife, our surgical education fellows reflect on what they wish they had known before Day 1—and all the humbling, hilarious, and genuinely formative moments along the way. From getting lost wheeling a critical patient through the hospital, to triple-scrubbing just to be acknowledged, to accidentally spraying TPA into your own eye (yes, really)—this episode is a candid conversation about the highs, lows, and everything in between. Whether you're gearing up to start your intern year or reflecting on how far you've come, this is the episode we all needed. Hosts:  Elizabeth Maginot, MD – General Surgery Resident, University of Nebraska Medical Center  @e_magination95 Nina Clark, MD – General Surgery Resident, University of Washington @clarkninam Ayman Ali, MD – General Surgery Resident, Duke University Michelle LaBella, MD – General Surgery Resident, University of North Carolina Emma Burke, MD – General Surgery Resident, Baylor College of Medicine @emmaburke017 Learning Objectives: Identify common misconceptions about intern year—and how to manage expectations Understand how to approach early mistakes with humility and resilience Recognize the importance of teamwork and asking for help Reflect on what makes a strong, dependable intern References BTK Intern Survival Guide: https://app.behindtheknife.org/podcast-series/medical-student-and-intern-survival-guide Institutional pharmacists (seriously, call them—they're the unsung heroes) Check out our Medical Student and Intern Survival Guide HERE: https://app.behindtheknife.org/podcast-series/medical-student-and-intern-survival-guide

Can we do more than prescribe pills to address men's sexual health complaints? In this episode of the BackTable Urology Podcast, men's health expert Dr. Mohit Khera from Baylor College of Medicine joins guest host Dr. Amy Pearlman for a deep dive into testosterone management and the full spectrum of erectile dysfunction therapies. --- SYNPOSIS The conversation covers daily tadalafil use, lifestyle optimization, and the nuanced role of off-label medications. Dr. Khera also highlights emerging technologies like the Tech Ring and radiofrequency treatments, alongside practical insights into semen analysis and hormonal health markers. Throughout, he emphasizes a holistic, patient-centered approach to sexual health—blending medical therapy with meaningful lifestyle change. This is a must-listen for general urologists, men's health specialists, and trainees looking to expand their toolkit in this evolving field. --- TIMESTAMPS 00:00 - Introduction02:13 - Erectile Dysfunction and Testosterone08:05 - Young Men's Health and Early Detection10:20 - Semen Analysis for Overall Health12:50 - Daily Tadalafil and Its Benefits16:40 - Proactive Sexual Health Management21:28 - Female Sexual Health25:16 - Treating Delayed Ejaculation28:53 - Psychogenic Erectile Dysfunction31:16 - Technology in Sexual Health35:54 - Lifestyle Modifications for Better Sexual Health41:55 - Resources and Referrals for Patients44:30 - Final Thoughts

Dr. Larry Lipshultz. is one of the world's leading experts in men's reproductive health. In this week's episode, we discuss testosterone therapy, male fertility, and the hidden environmental factors threatening men's health. Dr. Lipshultz shares groundbreaking insights into why male fertility is declining, common myths surrounding testosterone and prostate cancer, and innovative strategies to safely enhance men's reproductive and overall health.We cover: The alarming 50% drop in male fertility since the 1980s—and what's driving itTestosterone therapy myths: prostate cancer, fertility, and what's actually truePractical treatments for restoring fertility while on testosterone therapyAnabolic agents: risks, benefits, and smart usePersonalized, patient-centered care to optimize male reproductive and overall healthIf you care about men's health, fertility, or hormone optimization, this conversation is a must-listen.Who is Dr. Larry Lipshultz? Dr. Lipshultz's research focuses on male reproductive dysfunction, testosterone therapy, cardiovascular risk, and the genetics of infertility. He has pioneered innovations in testicular sperm extraction, vasectomy reversal, and testosterone optimization therapies. With over 460 peer-reviewed publications and as co-author of a foundational textbook on andrology, his contributions have significantly enhanced diagnostic approaches in male infertility. An early recipient of the American Urological Association Research Scholar award, he advocates for integrative andrologic health as a foundation for lifelong wellness.This episode is brought to you by: Puori - Get 20% off sitewide with Code DRLYON - https://Puori.com/DRLYONCozy Earth - Use code DRLYON for up to 40% off - https://cozyearth.comTimeline - Get 20% off your order of Mitopure - https://timeline.com/LYONManukora - Get $25 off the Starter Kit - https://manukora.com/DRLYONFind Dr. Lipshultz at: Website - https://www.larrylipshultz.com/Baylor College of Medicine - https://www.bcm.edu/people-search/larry-lipshultz-25437 LinkedIn - https://www.linkedin.com/in/larry-lipshultz-md-93977344/ Find Me At: Instagram:@drgabriellelyon TikTok: @drgabriellelyonFacebook: facebook.com/doctorgabriellelyonYouTube: youtube.com/@DrGabrielleLyonX (Twitter): x.com/drgabriellelyonApply to become a patient – https://drgabriellelyon.com/new-patient-inquiry/Join my weekly newsletter –

Markets fall as President Trump threatens to increase tariffs on Apple and the European Union. Former Chancellor of the University of North Carolina Chapel Hill Holden Thorp discusses his concerns over the Trump administration's attack on higher education. Baylor College of Medicine Dean Dr. Peter Hotez explains the new COVID-19 vaccine formula and guidance from the FDA. NBC News White House Correspondent Yamiche Alcindor reports on the reality of Trump's campaign promise to expand access to IVF.